Wenbin Zhang1, Yi Luan1, Chongying Jin1, Shengjie Xu1, Xukun Bi1, Yanbo Zhao1, Fuyu Qiu1, Guosheng Fu2, Min Wang3. 1. Department of Cardiology, Biomedical Research (Therapy) Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, Zhejiang, China. 2. Department of Cardiology, Biomedical Research (Therapy) Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, Zhejiang, China. fugs@medmail.com.cn. 3. Department of Cardiology, Biomedical Research (Therapy) Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, Zhejiang, China. wangmin_hzzjusyf@yeah.net.
Abstract
INTRODUCTION: More and more evidence suggests that the density of calcification plays an important role in the plaque stability. However, few studies have investigated the statin treatment on the density of plaque calcification in patients with both coronary artery disease (CAD) and type 2 diabetes mellitus. METHODS: One hundred and twenty-two CAD patients with type 2 diabetes with confirmed coronary artery calcification (CAC) will be recruited consecutively in a 12-month period. These patients will receive rosuvastatin (20 mg/day) therapy in the next 24 months. Blood tests and adverse events will be collected at routine follow-up of 1, 3, 6, 12, 18 and 24 months. The primary endpoint will be the change of CAC density score measured by coronary CT angiography after 24 months' treatment of rosuvastatin (20 mg/day) compared with baseline. The secondary endpoints will be the change of serum sclerostin and the effect on the volume score of CAC in those patients. RESULTS: We expect that rosuvastatin could both increase the density of CAC to improve plaque stability and up-regulate serum sclerostin, which would suggest the underlying mechanism of the plaque stabilization by a statin. CONCLUSION: This study would be the first to demonstrate the impact of rosuvastatin on the density score of coronary artery calcification in CAD patients with type 2 diabetes. This study has been registered in ClinicalTrials.gov (NCT02418884).
INTRODUCTION: More and more evidence suggests that the density of calcification plays an important role in the plaque stability. However, few studies have investigated the statin treatment on the density of plaque calcification in patients with both coronary artery disease (CAD) and type 2 diabetes mellitus. METHODS: One hundred and twenty-two CAD patients with type 2 diabetes with confirmed coronary artery calcification (CAC) will be recruited consecutively in a 12-month period. These patients will receive rosuvastatin (20 mg/day) therapy in the next 24 months. Blood tests and adverse events will be collected at routine follow-up of 1, 3, 6, 12, 18 and 24 months. The primary endpoint will be the change of CAC density score measured by coronary CT angiography after 24 months' treatment of rosuvastatin (20 mg/day) compared with baseline. The secondary endpoints will be the change of serum sclerostin and the effect on the volume score of CAC in those patients. RESULTS: We expect that rosuvastatin could both increase the density of CAC to improve plaque stability and up-regulate serum sclerostin, which would suggest the underlying mechanism of the plaque stabilization by a statin. CONCLUSION: This study would be the first to demonstrate the impact of rosuvastatin on the density score of coronary artery calcification in CAD patients with type 2 diabetes. This study has been registered in ClinicalTrials.gov (NCT02418884).
Authors: Alexander W Leber; Andreas Knez; Carl W White; Alexander Becker; Franz von Ziegler; Olaf Muehling; Christoph Becker; Maximilian Reiser; Gerhard Steinbeck; Peter Boekstegers Journal: Am J Cardiol Date: 2003-03-15 Impact factor: 2.778
Authors: Jun Pu; Gary S Mintz; Sinan Biro; Jin-Bae Lee; Stephen T Sum; Sean P Madden; Allen P Burke; Pei Zhang; Ben He; James A Goldstein; Gregg W Stone; James E Muller; Renu Virmani; Akiko Maehara Journal: J Am Coll Cardiol Date: 2014-03-26 Impact factor: 24.094
Authors: Vincent M Brandenburg; Rafael Kramann; Ralf Koos; Thilo Krüger; Leon Schurgers; Georg Mühlenbruch; Sinah Hübner; Ulrich Gladziwa; Christiane Drechsler; Markus Ketteler Journal: BMC Nephrol Date: 2013-10-10 Impact factor: 2.388
Authors: Sonia Morales-Santana; Beatriz García-Fontana; Antonia García-Martín; Pedro Rozas-Moreno; José Antonio García-Salcedo; Rebeca Reyes-García; Manuel Muñoz-Torres Journal: Diabetes Care Date: 2013-01-03 Impact factor: 19.112